Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-β

Journal of Neuroimmunology

Volumn 162, Issue 1-2, 2005, Pages 173-183

  Correale, Jorge ^a   Rush, Carolina ^a   Amengual, Alejandra ^a   Goicochea, María Teresa ^a  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

Antibodies; Cytokines; Interferon ; Mitoxantrone; Multiple sclerosis

Indexed keywords

BETA INTERFERON; GADOLINIUM; METHYLPREDNISOLONE; MITOXANTRONE; ONDANSETRON; PREDNISOLONE;

ADULT; AMENORRHEA; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE CALCULATION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; MALE; MEDICAL ASSESSMENT; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; SCORING SYSTEM;

EID: 17044391471     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2005.02.003     Document Type: Article

References (52)

1. G. Antonelli, F. Bognato, C. Pozzilli, E. Simeoni, S. Bastianelli, M. Currenti, F. De Pisa, C. Fieschi, C. Gasperini, M. Salvetti, and F. Dianzani Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta 1a J. Interferon Cytokine Res. 18 1998 345 350
2. P. Barbero, A. Pipieri, E. Verdun, M. Clerico, A. Ricci, M.A. Cucci, L. Giordeno, E. Cartechini, G. Giuliani, E. Montanari, M. Bergui, and L. Durelli High-dose interferon-β-1b (500 mcg every-other day subcutaneously) treatment in MS patients. Long term evaluation and longitudinal comparison with preceding treatment with lower IFN-β dose Mult. Scler. 10 Suppl. 2 2004 S248
3. A.A. Byrnes, J.C. McArthur, and C.L. Karp Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production Ann. Neurol. 51 2002 165 174
4. P.A. Calabresi, L.A. Stone, C.N. Bash, J.A. Frank, and H.F. McFarland Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI Neurology 48 1997 1446 1448
5. J.A. Cohen, J.L. Carter, R.P. Kinkel, and S.R. Schwid Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders J. Neuroimmunol. 98 1999 29 36
6. M. Comabella, K. Balashov, S. Issazadeh, D. Smith, H.L. Weiner, and S.J. Khoury Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy J. Clin. Invest. 102 1998 671 678
7. C. Confavreaux Combination therapies in multiple sclerosis J.A. Cohen R.A. Rudick Multiple sclerosis therapeutics 2003 Martin Dunitz London 523 533
8. J. Correale, and M. Bassani Molinas Oligoclonal bands and antibody responses in multiple sclerosis J. Neurol. 249 2002 375 389
9. J. Correale, and M. Bassani Molinas Time course of T-cell responses to MOG and MBP in patients with clinically isolated syndromes J. Neuroimmunol. 136 2003 162 171
10. S. Dhib-Jalbut Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis Neurology 58 2002 S3 S9
11. L. Durelli, E. Verdun, P. Barbero, A. Pipieri, A. Ricci, M. Clerico, M.A. Cucci, L. Giordano, M. Bergui, and E. Versino Interferon-β-1b in multiple sclerosis: comparing two different doses (the OPTIMS study) Mult. Scler. 10 Suppl. 2 2004 S248
12. G. Edan, D. Miller, M. Clanet, C. Confavreaux, O. Lyon-Caen, C. Lubetzki, B. Brochet, I. Berry, Y. Rolland, J.C. Froment, E. Cabanis, M.T. Iba-Zizen, J.M. Gandon, H.M. Lai, I. Moseley, and O. Sabouraud Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria J. Neurol. Neurosurg. Psychiatry 62 1997 112 118
13. G. Edan, S.P. Morrisey, and H.P. Hartung Use of mitoxantrone to treat multiple sclerosis J.A. Cohen R.A. Rudick Multiple sclerosis therapeutics 2003 Martin Dunitz London 403 426
14. D. Faulds, J.A. Balfour, P. Chrisp, and H.D. Langtry Mitoxantrone: a review of its pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer Drugs 41 1991 400 499
15. J.M. Fidler, S.Q. DeJoy, and J.J. Gibbons Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone: I. Suppression of B lymphocyte function J. Immunol. 137 1986 727 732
16. R.J. Fox, and R.P. Kinkel Treatment of multiple sclerosis with methylprednisolone J.A. Cohen R.A. Rudick Multiple sclerosis therapeutics 2003 Martin Dunitz London 461 482
17. T.F. Gajewski, S.R. Schell, G. Nau, and F.W. Fitch Regulation of T cell activation: differences among T-cell subsets Immunol. Rev. 111 1989 79 110
18. C.P. Genain, M.H. Nguyen, N.L. Letvin, R. Pearl, R.L. Davis, M. Adelman, M.B. Lees, C. Linington, and S.L. Hauser Antibody facilitation of multiple sclerosis-like lesions in a non human primate J. Clin. Invest. 96 1995 2966 2974
19. R.E. Gonsette Mitoxantrone immunotherapy in multiple sclerosis Mult. Scler. 1 1996 329 332
20. D.S. Goodin, B.G. Arnason, P.K. Coyle, E.M. Frohman, and D.W. Paty The use of Mitoxantrone (Novantrone) for the treatment of multiple sclerosis Neurology 61 2003 1332 1338
21. J.L. Haines, H.A. Terwedow, K. Burgess, M.A. Pericak-Vance, J.B. Rimmler, E.R. Martin, J.R. Oksenberg, R. Lincoln, D.Y. Zhang, D.R. Banatao, N. Gatto, D.E. Goodkin, and S.L. Hauser Linkage of the MHC to familial multiple sclerosis suggest genetic heterogeneity. The Multiple Sclerosis Genetics Group Hum. Mol. Genet. 7 1998 1229 1234
22. H.P. Hartung, R. Gonsette, N. König, H. Kwiecinski, A. Guseo, S.P. Morrisey, H. Krapf, T. Zwingers Mitoxantrone in Multiple, Sclerosis Study Group (MIMS) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double blind, randomised, multicentre trial Lancet 360 2002 2018 2025
23. L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.M. Herndon, J.R. Richert, A.M. Salazar, J.S. Fischer, D.E. Goodkin, C.V. Granger, J.H. Simon, J.J. Alam, D.M. Bartoszak, D.M. Bourdette, J. Braiman, C.M. Brownschdeile, M.E. Coats, S.L. Cohan, D.S. Dougherty, R.P. Kinkel, M.K. Mass, F.E. Munschauer III, R.L. Priore, P.M. Pullicino, B.J. Scherokman, and R.H. Whitam Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Ann. Neurol. 39 1996 285 294
24. H. Lenk, U. Müller, and S. Tannenmberger Mitoxantrone: mechanisms of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity Anticancer Res. 7 1987 1257 1264
25. J.P. Leonard, K.E. Waldburger, and S.J. Goldman Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin-12 J. Exp. Med. 181 1995 381 386
26. E. Le Page, M. Counstans, N. Mauduit, G. Taurin, O. De Marco, J. Chaperon, and G. Edan Induction treatment with monthly mitoxantrone- methylprednisolone for 6 months in worsening relapsing-remitting multiple sclerosis: the clinical benefit lasts at least 4 years Mult. Scler. 7 Suppl. 1 2001 S63
27. C. Linington, M. Bradl, H. Lassman, C. Brunner, and K. Vass Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein Am. J. Pathol. 130 1988 443 454
28. F. Lolli, G. Siracusa, M.P. Amato, L. Fratiglioni, G. Dal Pozzo, E. Galli, and L. Amaducci Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis Acta Neurol. Scand. 83 1991 239 243
29. F.D. Lublin, M. Lavasa, C. Viti, and R.L. Knobler Suppression of acute relapsing experimental allergic encephalomyelitis with mitoxantrone Clin. Immunol. Immunopathol. 45 1987 122 128
30. C. Lucchinetti, W. Bruck, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann. Neurol. 47 2000 707 717
31. R. Manetti, M.G. Parronchi, M.P. Giudice, M.P. Piccinni, E. Maggi, G. Trinchier, and S. Romagnani Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4 producing Th cells J. Exp. Med. 177 1993 1199 1204
32. E. Millefiorini, C. Gasperini, C. Pozzilli, F. D'Andrea, S. Bastianello, M. Trojano, S. Morino, V.B. Morra, A. Bozazo, A. Calo, M.L. Bernini, D. Gambi, and M. Prencipe Randomised placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: a 24-month clinical and MRI outcome J. Neurol. 244 1997 153 159
33. J.J. O'Shea, A. Ma, and P. Lipsky Cytokines and autoimmunity Nat. Rev., Immunol. 2 2002 37 45
34. V. Özency, M. Kouwenhoven, N. Teleshova, M. Pashenkov, S. Fredrikson, and H. Link Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β J. Neuroimmunol. 108 2000 236 243
35. H.S. Panitch, R.L. Hirsch, J. Schindler, and K.P. Johnson Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system Neurology 37 1987 1097 1102
36. B. Popko, J.G. Corbin, K.D. Baerwald, J. Dupree, and A.M. Garcia The effects of Interferon-gamma on the central nervous system Mol. Neurobiol. 14 1997 19 35
37. PRISMS Study Group University of British Columbia MS/MRI Analysis Group PRISMS-4: long term efficacy of interferon-beta-1a in relapsing MS Neurology 56 2001 1628 1636
38. C.S. Raine The Dale McFarlin memorial lecture: the immunology of multiple sclerosis lesions Ann. Neurol. 36 1994 S61 S72
39. C.S. Raine, B. Canella, S.L. Hauser, and C.P. Genain Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation Ann. Neurol. 46 1999 144 160
40. S.C. Ridge, A.E. Sloboda, R.A. McReynolds, S. Levine, A.L. Oronsky, and S.S. Kerw Suppression of experimental allergic encephalomyelitis by mitoxantrone Clin. Immunol. Immunopathol. 35 1985 35 42
41. R.A. Rudick, R.M. Ransohoff, J.C. Lee, R. Peppler, M. Yu, P.M. Mathisen, and V.K. Tuohy In vivo effects of interferon beta 1-a on immunosuppressive cytokines in multiple sclerosis Neurology 50 1998 1294 1300
42. M.K. Sharief, and E.J. Thompson Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters Brain 114 1991 181 195
43. C.J.M. Sindic, P. Monteyne, and E.C. Laterre Occurrence of oligoclonal IgM bands in the cerebrospinal fluid of neurological patients: an immunoaffinity-mediated capillary blot study J. Neurol. Sci. 124 1994 215 219
44. L. Steinman Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system Cell 85 1996 299 302
45. P. Stinissen, J. Raus, and J. Zhang Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies Crit. Rev. Immunol. 17 1997 33 75
46. L.A. Stone, J.A. Frank, P.S. Albert, C.N. Bash, P.A. Calabresi, H. Maloni, and H.F. McFarland Characterization of MRI response to treatment with interferon bata-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure Neurology 49 1997 862 869
47. K. Takatsu Cytokines involved in B-cell differentiation and their sites of action Proc. Soc. Exp. Biol. Med. 215 1997 121 133
48. The IFN Multiple Sclerosis Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial Neurology 43 1993 655 661
49. L.M. Villar, J. Masjuan, P. Gonzalez-Porqué, J. Plaza, M.C. Sabada, E. Roldan, A. Bootello, and J.C. Alvarez-Cermeno Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS Neurology 59 2002 555 559
50. K.P. Wandinger, C.S. Sturzebecher, B. Bielekova, B. Bielekova, G. Detore, A. Rosenwald, L.M. Staudt, H.F. McFarland, and R. Martin Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes Ann. Neurol. 50 2001 349 357
51. B.S. Wang, A.L. Lumanglas, V.M. Ruszala-Mallon, R.E. Wallace, and F.E. Durr Induction of alloreactive immunosuppression by 1-4 bis [(2-aminoethyl) amino]-5,8-dihydroxy-9,10-anthracenedione dihydrochloride (CL 232,468) Int. J. Immunopharmacol. 6 1984 475 482
52. C.M. Watson, A.N. Davison, D. Baker, J.K. O'Neill, and J.L. Turk Suppression of demyelination by mitoxantrone Int. J. Immunopharmacol. 13 1991 923 930